DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,883,780 B2 Aret (45) Date of Patent: Nov

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,883,780 B2 Aret (45) Date of Patent: Nov US008883780B2 (12) United States Patent (10) Patent No.: US 8,883,780 B2 Aret (45) Date of Patent: Nov. 11, 2014 (54) CRYSTAL OF A BENZOXAZINONE (56) References Cited COMPOUND U.S. PATENT DOCUMENTS (75) Inventor: Edwin Aret, Amsterdam (NL) 6,624,161 B2 * 9/2003 Hodson et al. ............. 514,230.5 6,656,934 B2 * 12/2003 Hodson et al. ............. 514,230.5 (73) Assignee: Norgine B.V., Amsterdam (NL) 7,396,952 B2 7/2008 Holzer et al. 2003/0027821 A1 2/2003 Hodson et al. 2003/0195206 A1 10, 2003 Hodson et al. *) Notice: Subject to anyy disclaimer, the term of this 2007/0232825 A1 10, 2007 Holzer et al. patent is extended or adjusted under 35 2008. O161301 A1 7/2008 Hodson et al. U.S.C. 154(b) by 241 days. 2008.0171891 A1 7/2008 Holzer et al. (21) Appl. No.: 13/265,599 FOREIGN PATENT DOCUMENTS JP 2006169244 A 6, 2006 (22) PCT Filed: Apr. 22, 2010 WO WO-00, 40247 A1 T 2000 WO WOOO4O247 A1 * T 2000 (86). PCT No.: PCT/UP2010/0571 10 WO WOOO40569 A1 * T 2000 S371 (c)(1), OTHER PUBLICATIONS (2), (4) Date: Dec. 22, 2011 English Translation of the International Preliminary Report on Pat entability for PCT/JP2010/0571 10 mailed Dec. 1, 2011. (87) PCT Pub. No.: WO2010/123047 Extended European Search Report for 10767104.2, 6 pages (Sep. 27. 2012). PCT Pub. Date: Oct. 28, 2010 International Search Report of PCT/JP2010/0571 10 mailed Jun. 22, 2010. (65) Prior Publication Data * cited by examiner US 2012/0101090 A1 Apr. 26, 2012 Primary Examiner — Kahsay Habte (30) Foreign Application Priority Data (74) Attorney, Agent, or Firm — Choate, Hall & Stewart, LLP; Charles E. Lyon; John P. Rearick Apr. 24, 2009 (JP) ................................. 2009-106.606 (57) ABSTRACT Disclosed is a crystal of 2-(hexadecyloxy)-6-methyl-4H-3, 1 (51) Int. Cl. benzoxazin-4-one useful as a preventive or therapeutic agent CO7D 265/26 (2006.01) for obesity and the like. Specifically disclosed is a crystal of A6 IK3I/536 (2006.01) 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one hav (52) U.S. Cl. ing a powder X-ray diffraction pattern in which characteristic USPC .......................................... 514/230.5:544/93 peaks appearat powder X-ray diffraction interplanar spacings (58) Field of Classification Search (d) of around 16.54+0.2, 13.26+0.2, 4.70+0.2, 4.38+0.2, and USPC .......................................... 514/230.5:544/93 3.67.0.2. See application file for complete search history. 3 Claims, 1 Drawing Sheet U.S. Patent Nov. 11, 2014 US 8,883,780 B2 ig, &Yo-YYYYYYYYYYYYYYYxxxxtreexYs Y*.xxxxwywww.www.x.................... SS s s s s |R. S. s s S. S: was versm xxxii. & Sssssssssssssssssssssss8.- S Stfeast ps: *''x''xs'-xxx-xx-xx-xx-x-xx-asssssssssssssssssssss------------------------- assaxoss-ex a-sasssssssssssssssssssssss | s&Syss $$$$.&swaxx's s $$$. $8,88 US 8,883,780 B2 1. 2 CRYSTAL OF A BENZOXAZNONE aZinone compound) of the present invention can be a solvate COMPOUND Such as a hydrate, etc., or a non-Solvate. The aforementioned hydrate, for example, can be between RELATED APPLICATIONS 0.5 hydrate and 5.0 hydrate. Preferable among these area 0.5 hydrate, 1.0 hydrate, 1.5 hydrate, 2.0 hydrate and 2.5 hydrate. This application is a national phase application under 35 The 0.5 hydrate, 1.0 hydrate and 1.5 hydrate are particularly U.S.C. 371 of PCT International Application No. PCT/ advantageous. JP2010/0571 10 (published PCT application no. WO 2010/ The benzoxazinone compound of the present invention or 123047), filed Apr. 22, 2010, which claims priority to Japa hydrate thereof may also be a deuterium converter. nese Application No. 2009-106606, filed Apr. 24, 2009, the 10 The benzoxazinone compound crystal of the present inven contents of which are hereby incorporated by reference in tion can also be a solvate other than a hydrate. their entirety for all purposes. Examples of Solvate crystal of benzoxazinone compound TECHNICAL FIELD include alcohol Solvate crystals such as methanol Solvate crystal and ethanol solvate crystal (preferably C alcohol The present invention relates to a crystal of benzoxazinone 15 Solvate crystal) and organic solvent hydrate crystal with compound that is useful in the prevention and treatment of added water and organic solvent (e.g., alcohol hydrate crystal obesity. Such as methanol hydrate crystal and ethanol hydrate crystal; preferably Calcohol hydrate crystal). BACKGROUND ART The crystal of the present invention can be manufactured by crystal transition using either a non-crystal benzoxazinone The use of 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzox compound or other crystal benzoxazinone compound. azin-4-one having the action of lipase inhibition has been In crystal transition, the crystal structure undergoes a reported as useful in the prevention and treatment of obesity, change above a certain temperature or pressure. etc., in the specification of U.S. Pat. No. 6,624,161. Examples of the Crystal Transition Method include those 25 known in the art, Such as crystallization from liquid (e.g., the OUTLINE OF THE INVENTION concentration method, slow-cooling method, reaction An agent is needed that is highly effective and safe in the method diffusion method, electrolysis method, hydrother prevention and treatment of obesity. The present invention mal cultivation method and fusing method, etc.), crystalliza aims to submit a new crystal of 2-(Hexadecyloxy)-6-methyl tion from vapor (vaporization method sealed tube method, 4H-3,1-benzoxazin-4-one that is useful as an agent of pre 30 gas flow method, gas phase reaction method, chemical trans vention and treatment of obesity. port method), crystallization from melt normal freezing As a result of intensive research, the present inventor Suc method (pull-up method, temperature gradient method, ceeded in producing a crystal of2-(Hexadecyloxy)-6-methyl Bridgeman method), Zone melting method Zone leveling 4H-31-benzoxazin-4-one (Cetilistat) that is extremely safe; method, float Zone method, special growth method VLS discovered that said crystal is pharmaceutically acceptable, 35 method, liquid phase epitaxy method), steam fog method and based on this knowledge, completed the present inven dissolving crystal in a solvent, and after filtration evaporat tion. ing the solvent under atmospheric conditions, slurry method That is, the present invention relates to: adding crystal to solvent to form a liquid Suspension of (1) A crystal of 2-(Hexadecyloxy)-6-methyl-4H-3,1-ben excess Solid, and after agitation at atmospheric temperature or Zoxazin-4-one with lattice spacing (d) of the powder 40 under heating or cooling conditions, filtering of the Solid. X-ray diffraction pattern characteristically peaking in reduced-pressure drying, grinding, pulverization and pressur the vicinity of 16.54+0.2, 13.26+0.2, 4.70+0.2, 4.38+0.2 ization. and 3.67+0.2, angstroms, Among the aforementioned methods, the slurry method is (2) A pharmaceutical containing the crystal of aforemen particularly favorable for obtaining the crystal of the present tioned (1), 45 invention. Particularly advantageous is the method whereby a (3) Pharmaceuticals, etc., of aforementioned (2) which are crystal of benzoxazinone compound is added to a Suspension agents for prevention and treatment of obesity. of excess Solid in a solvent and, after agitation, the Solid is filtered off. Examples of the solvent to use include aromatic EFFECTIVENESS OF THE INVENTION hydrocarbons (e.g., benzene, toluene and Xylene), hydrocar 50 bon halides (e.g., dichloromethane, chloroform, etc.), satu The crystal of the present invention (e.g., hereinafter rated hydrocarbons (e.g., hexane, heptane, cyclohexane, referred to as A-type crystal and B-type crystal) is useful as a etc.), ethers (e.g., diethyl ether, diisopropyl ether, tetrahydro pharmaceutical having exceptional lipase inhibiting action foran, dioxane etc.), nitryls (e.g., acetonitryl, etc.), ketones and lipid absorption controlling action, as well as low toxic (e.g., acetone, etc.), Sulfoxides (e.g., dimethyl Sulfoxide, 1ty. 55 etc.), acid amides (e.g., N,N-dimethylformamide, etc.), esters (e.g., acetic ether, etc.), alcohols (e.g., methanol, ethanol, SIMPLE EXPLANATION OF DIAGRAMS isopropyl alcohol, etc.), and water. These solvents can be used alone or two or more can be used in a mixture of suitable ratio FIG. 1 shows a powder X-ray diffraction pattern of the (e.g., 1:1 or 1:100). It is advantageous to use aromatic hydro B-type crystal of preferred embodiment 1. 60 carbons (e.g., Xylene), ethers (e.g., tetrahydrofuran, etc.), and FIG. 2 shows a powder X-ray diffraction pattern of the preferably ethers (e.g., tetrahydrofuran, etc.). A-type crystal of reference embodiment 1. The volume of solvent to use is normally approx. 2.5 ml-approx. 10 ml per 1 g of benzoxazinone compound crys DETAILED DESCRIPTION OF THE INVENTION tal, and preferably approx. 2.5 ml-approx. 3 ml. 65 After agitating the liquid Suspension at atmospheric tem The crystal 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzox perature, it is advisable to cool and agitate again. In the azin-4-one (or otherwise abbreviated hereinafter to benzox specification of the present invention, room temperature and US 8,883,780 B2 3 4 atmospheric temperature mean approx. 15° C.-approx. 30° postprandial hyperlipidemia), hyperglycemia (type II diabe C. The period for agitation at atmospheric temperature is tes, impaired glucose tolerance), high blood pressure, cardio normally approx. 2 hours-approx. 24 hours; preferably vascular disease, cerebral stroke, gastrointestinal disease, approx. 15 hours-approx. 24 hours. The period of agitation etc., or complications thereof (e.g., complications of type II under cooling is normally approx. 4 hours-approx 24 hours; diabetes, complications of hyperlipidemia and metabolic preferably approx.
Load more

Recommended publications
  • (200731) Hypromellose Phthalate (220824) Ibudilast
    21222122 Infrared Reference Spectra JP XVII Hypromellose Phthalate (200731) Hypromellose Phthalate (220824) Ibudilast The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21232123 Ibuprofen Ibuprofen Piconol Ifenprodil Tartrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21242124 Infrared Reference Spectra JP XVII Imidapril Hydrochloride Imipenem Hydrate Indapamide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21252125 Indenolol Hydrochloride Indometacin Iohexol The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21262126 Infrared Reference Spectra JP XVII Iopamidol Iotalamic Acid Iotroxic Acid The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
    [Show full text]
  • An Ultra Fast and Sensitive Detection of 165 Drugs of Abuse in Human Urine Using Polarity Switching Ultra Performance Liquid Chromatog- Raphy Tandem Mass Spectrometry
    id15306796 pdfMachine by Broadgun Software - a great PDF writer! - a great PDF creator! - http://www.pdfmachine.com http://www.broadgun.com AAnnaallyyttiiccaaIlSlS N : 0974-7419 Volume 15 Issue 8 CCHHEEAMMn InIdIiSSanTT JoRuRrnYaYl Full Paper ACAIJ, 15(8) 2015 [319-338] An ultra fast and sensitive detection of 165 drugs of abuse in human urine using polarity switching ultra performance liquid chromatog- raphy tandem mass spectrometry Sachin Dubey, Shobha Ahi, Alka Beotra*, Tejinder Kaur, Shila Jain National Dope Testing Laboratory, Ministry of Youth Affairs and Sports, CGO Complex, Lodhi Road, New Delhi, 110003, (INDIA) E-mail : [email protected] ABSTRACT KEYWORDS The screening of wide variety of prohibited substances in a time bound Bioanalytical method; manner by adhering to latest World Anti-Doping Agency (WADA) guide- Sports drug testing; lines is a challenging task for doping control laboratories. The revised crite- UPLC-MS/MS; rion of detection limits (WADATD2013MRPL) has further required the doping Polarity switching; laboratories to review their testing procedures. The present work was aimed WADA. at developing a fast, sensitive and robust analytical method based on solid phase cleanup (SPE) and ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to achieve the required detection lev- els. The method development involved optimization of deconjugation of phase II metabolites, SPE using mixed-mode ion cartridges for extraction of analytes of wider chemistries; and fast polarity switching UPLC-MS/MS detection. The developed method was validated to detect approximately 165 compounds and/or metabolites prohibited by WADA. The eight min- utes runtime allowed testing of approximately 180 samples in 24 hours at the limit of detection (LOD) of 50% below required detection levels.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Drugs for Complications of Diabetes and Neuropathy and Utilization Thereof
    Europäisches Patentamt *EP001283054A1* (19) European Patent Office Office européen des brevets (11) EP 1 283 054 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 45/00, A61K 31/198, 12.02.2003 Bulletin 2003/07 A61P 3/10, A61P 25/00, A61P 9/00, A61P 13/12 (21) Application number: 01912425.4 (86) International application number: (22) Date of filing: 15.03.2001 PCT/JP01/02094 (87) International publication number: WO 01/068136 (20.09.2001 Gazette 2001/38) (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • KITAHARA, Yoshiro, Pharmaceutical Res. Lab. MC NL PT SE TR Kawasaki-shi, Kanagawa 210-8681 (JP) Designated Extension States: • MIURA, Kyoko, Pharmaceutical Res. Lab. AL LT LV MK RO SI Kawasaki-shi, Kanagawa 210-8681 (JP) (30) Priority: 17.03.2000 JP 2000076542 (74) Representative: Nicholls, Kathryn Margaret et al MEWBURN ELLIS (71) Applicant: Ajinomoto Co., Inc. York House Tokyo 104-8315 (JP) 23 Kingsway London WC2B 6HP (GB) (54) DRUGS FOR COMPLICATIONS OF DIABETES AND NEUROPATHY AND UTILIZATION THEREOF (57) There are provided a medicament excellent in ments, and the like are provided. At least one agent se- prevention, improvement, treatment, etc. of a diabetic lected from an antihypertensive agent, a vasodilating complication, and a medicament excellent in preven- agent and an anti-hyperlipidemic agent may be used at tion, improvement, treatment, etc. of a neuropathy, each the same time with the postprandial blood sugar-lower- using a postprandial blood sugar-lowering agent as an ing agent, by mixing further such at least one agent se- effective ingredient therefor.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • I in Un Torn Untuk Ta in an Atau Mana Na Anth
    IIN UN TORN UNTUKTAUS IN20170304388A1 AN ATAU MANA NA ANTH ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017/ 0304388 A1 Chen et al. ( 43 ) Pub . Date: Oct. 26 , 2017 (54 ) NEW INDICATION OF CARDIOVASCULAR A61K 31/ 549 ( 2006 . 01 ) DRUGS FOR PREPARATION OF CANCER A61K 31 /505 (2006 .01 ) INHIBITION PHARMACEUTICAL A61K 31 / 404 ( 2006 .01 ) COMPOSITION A61K 31 / 366 ( 2006 .01 ) A61K 31 /341 ( 2006 . 01 ) (71 ) Applicant : LAUNX BIOMEDICAL CO ., LTD . , A61K 31 /216 ( 2006 .01 ) Kaohsiung ( TW ) A61K 31 / 197 (2006 .01 ) A61K 31 / 196 ( 2006 .01 ) ( 72 ) Inventors : Chiu -Hung Chen , Kaohsiung ( TW ) ; A61K 45 / 06 ( 2006 . 01 ) Show -Mei Chuang, Taichung ( TW ) ; A61K 31 / 138 ( 2006 . 01) Nai- Wan Hsiao , Taichung ( TW ) ; (52 ) U . S . CI. Ruei - Yue Liang , Taichung ( TW ) ; CPC .. .. .. .. A61K 38 /05 (2013 . 01 ) ; A61K 45 / 06 Xiao - Tong Tan , Taichung ( TW ) ( 2013 .01 ) ; A61K 31 / 7056 ( 2013 .01 ) ; A61K 31/ 55 (2013 .01 ) ; A61K 31 /549 ( 2013 .01 ) ; ( 73 ) Assignee : LAUNX BIOMEDICAL CO ., LTD ., A61K 31 /505 ( 2013 . 01 ) ; A61K 31/ 138 Kaohsiung ( TW ) (2013 . 01 ) ; A61K 31/ 366 ( 2013 . 01 ) ; A61K 31/ 341 ( 2013 .01 ) ; A61K 31/ 216 ( 2013 .01 ) ; (21 ) Appl. No. : 15 /521 , 536 A61K 31 / 197 (2013 . 01 ) ; A61K 31/ 196 ( 22 ) PCT Filed : Oct. 23 , 2015 ( 2013. 01 ) ; A61K 31/ 404 ( 2013. 01 ) ( 57 ) ABSTRACT ( 86 ) PCT No .: PCT/ CN2015 /092768 A method for treating a cancer includes administering to a $ 371 ( c ) ( 1 ) , subject in need thereof a pharmaceutical composition con ( 2 ) Date : Apr. 24 , 2017 taining a therapeutically effective amount of a cardiovascu lar drug or a pharmaceutical acceptable salt thereof.
    [Show full text]
  • In Vitro Inhibition of Breast Cancer Spheroid-Induced Lymphendothelial
    FULL PAPER British Journal of Cancer (2013) 108, 570–578 | doi: 10.1038/bjc.2012.580 Keywords: lymphendothelial intravasation; tumour spheroid; acetohexamide; nifedipin; isoxsuprine; proadifen In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen N Kretschy1,8, M Teichmann1,8, S Kopf1, A G Atanasov2, P Saiko3, C Vonach1, K Viola1, B Giessrigl1, N Huttary1, I Raab1, S Krieger1,WJa¨ ger4, T Szekeres3, S M Nijman5, W Mikulits6, V M Dirsch2, H Dolznig7, M Grusch6 and G Krupitza*,1 1Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 2Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 4Department for Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 5Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, A-1090 Vienna, Austria; 6Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria and 7Institute of Medical Genetics, Medical University of Vienna, Waehringer Strasse 10, A-1090 Vienna, Austria Background: As metastasis is the prime cause of death from malignancies, there is vibrant interest to discover options for the management of the different mechanistic steps of tumour spreading. Some approved pharmaceuticals exhibit activities against diseases they have not been developed for. In order to discover such activities that might attenuate lymph node metastasis, we investigated 225 drugs, which are approved by the US Food and Drug Administration.
    [Show full text]
  • A Pharmaceutical Composition for Angiotensin Ii-Mediated Diseases
    (19) & (11) EP 2 277 520 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.01.2011 Bulletin 2011/04 A61K 31/4184 (2006.01) A61K 31/341 (2006.01) A61K 31/4245 (2006.01) A61K 31/496 (2006.01) (2006.01) (2006.01) (21) Application number: 10178599.6 A61K 31/5415 A61K 45/06 A61P 9/12 (2006.01) A61P 9/10 (2006.01) (2006.01) (2006.01) (22) Date of filing: 07.06.1994 A61P 9/00 A61P 13/12 A61P 5/00 (2006.01) A61P 17/00 (2006.01) A61P 25/00 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) A61P 25/22 (2006.01) A61P 27/06 (2006.01) (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL • Inada, Yoshiyuki PT SE Hyogo 666 (JP) • Kubo, Keiji (30) Priority: 07.06.1993 JP 13552493 Osaka 562 (JP) (62) Document number(s) of the earlier application(s) in (74) Representative: Kalhammer, Georg et al accordance with Art. 76 EPC: Lederer & Keller 07014995.0 / 1 844 774 Patentanwälte 03001570.5 / 1 306 089 Prinzregentenstrasse 16 94108687.8 / 0 628 313 D-80538 München (DE) (71) Applicant: Takeda Pharmaceutical Company Remarks: Limited This application was filed on 23-09-2010 as a Osaka 541-0045 (JP) divisional application to the application mentioned under INID code 62. (54) A pharmaceutical composition for angiotensin ii-mediated diseases (57) This invention relates to a pharmaceutical com- wherein R1 is H or an optionally substituted hydrocarbon position for angiotensin mediatedII- diseases, which residue; R2 is an optionally esterified carboxyl group; R 3 comprises a compound having
    [Show full text]